Oncologic Outcome of Sacral Chordoma.
10.5292/jkbjts.2012.18.2.66
- Author:
Sang Hyun CHO
1
;
Soo Yong LEE
;
Dae Geun JEON
;
Won Seok SONG
;
Chang Bae KONG
;
Jung Dong LEE
;
Wan Hyeong CHO
Author Information
1. Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea. chowanda@naver.com
- Publication Type:Original Article
- Keywords:
sacrum;
chordoma;
prognostic factor
- MeSH:
Chordoma;
Female;
Follow-Up Studies;
Humans;
Male;
Neoplasm Metastasis;
Postoperative Complications;
Quality of Life;
Recurrence;
Retrospective Studies;
Sacrum;
Survival Rate
- From:The Journal of the Korean Bone and Joint Tumor Society
2012;18(2):66-71
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We analyzed treatment result to examine the outcome for patients with sacral chordoma and to determine relevant prognostic factors. MATERIALS AND METHODS: We retrospectively reviewed 19 patients with sacral chordoma seen at out institution between 1990 and 2010. There were 9 men and 10 women with mean age of 56 years. The average follow up was 63 months (range, 25-144 months). 15 patient received surgical treatment, six of these patient had wide, eight had marginal, one had intralesional margin and 4 patient treated with Radiation therapy only. RESULTS: The disease free and overall survival rate for all 19 patients was 34.7% and 79.7% at 5-years, respectively. Statistical analysis using the log-rank test revealed no significant difference between the surgery and radiation therapy groups in overall survival (p=0.54). Nine of 19 patients had local recurrence at a median of 2.5 years postoperatively. Seven of these 9 patients had distant metastasis at a median of 4.5 years postoperatively. Among the variables, tumor size (p=0.033) and tumor involvement of above S3 (p=0.032) were independent prognostic factor for overall survival. Nine of 15 patients who received surgical treatment had postoperative complication such as voiding difficulty and incontinence. CONCLUSION: Careful consideration of the patient general condition and predictable complication of the treatment might be the best way to improve patient's survival and quality of life.
